WO2018226051A2 - Serum-free medium composition for culturing cells including exosome derived from human stem cell - Google Patents

Serum-free medium composition for culturing cells including exosome derived from human stem cell Download PDF

Info

Publication number
WO2018226051A2
WO2018226051A2 PCT/KR2018/006488 KR2018006488W WO2018226051A2 WO 2018226051 A2 WO2018226051 A2 WO 2018226051A2 KR 2018006488 W KR2018006488 W KR 2018006488W WO 2018226051 A2 WO2018226051 A2 WO 2018226051A2
Authority
WO
WIPO (PCT)
Prior art keywords
serum
stem cells
cell culture
cell
medium
Prior art date
Application number
PCT/KR2018/006488
Other languages
French (fr)
Korean (ko)
Other versions
WO2018226051A3 (en
Inventor
조용우
최지숙
이찬미
김재동
Original Assignee
주식회사 엑소스템텍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엑소스템텍 filed Critical 주식회사 엑소스템텍
Publication of WO2018226051A2 publication Critical patent/WO2018226051A2/en
Publication of WO2018226051A3 publication Critical patent/WO2018226051A3/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/70Undefined extracts
    • C12N2500/80Undefined extracts from animals
    • C12N2500/84Undefined extracts from animals from mammals

Definitions

  • the present invention relates to a serum-free medium composition for culturing cells containing exosomes derived from human stem cells as an active ingredient, more specifically, containing exosomes derived from human stem cells, it is possible to minimize cell damage And a new serum-free medium composition for cell culture that can aid in cell adhesion and growth and induce and promote cell proliferation.
  • the present invention also relates to an animal serum replacement agent comprising an exosome derived from human stem cells, a serum-free medium composition for cell culture containing the same, and a method of culturing cells using the same.
  • the present invention can overcome the shortcomings of the serum by using a medium in which exosomes are added instead of animal serum, and can be applied to a serum-free medium composition for stem cell culture, thereby culturing stem cells without animal serum. And finally to a method for culturing stem cells for cell therapy for clinical applications.
  • Serum contains a variety of hormones in the insulin or polypeptide family that promote cell growth and function, growth factors that regulate cell division and function, and adhesion and diffusion factors such as fibronectin, transferrin as a binding protein, lipids and minerals. Many trace elements are included. Serum is also a buffer that regulates the osmotic pressure and pH of the culture, and has a viscous action that protects cells from proteolytic inhibition and physical shock. Cells can be cultured using serum containing these various functions.
  • Stem cells have the property of continuously producing the same cells as themselves for a certain period of time in an undifferentiated state, and differentiate into specific cells under suitable conditions.
  • Adult stem cells can be obtained from bone marrow, blood, brain, skin, and fat, and are known to be able to differentiate into various tissue cells.
  • adult stem cells such as adipose derived stem cells, bone marrow derived stem cells, umbilical cord or umbilical-cord blood derived stem cells Research into the development of autologous or other cell therapy is also actively underway.
  • animal serum may have a change in composition depending on the time and place of collection, it is difficult to administer to the patient stem cells cultured in a serum-containing medium.
  • the method of culturing stem cells by adding hormones, growth factors or purified proteins instead of serum is most commonly used. Although it is added to the basic medium by combining components necessary for adhesion and growth of stem cells such as amino acids, vitamins, insulin-like factors, epidermal growth factor, fibroblast growth factor, protease inhibitors, proteins and selenium, And growth factors are sold at a very high price, it is difficult to use a combination of various components.
  • exosomes are vesicles with the same membrane structure as cell membranes and are known to deliver membrane components, proteins, RNA, and the like to other cells and tissues.
  • exosomes secreted from stem cells contain various growth factors and cytokines secreted by stem cells, and are known to regulate cell adhesion, growth, and differentiation.
  • exosomes are removed impurities such as cell waste, antibiotics, serum in the cell culture in the separation process, it can be used safely and equivalent to the effect of the cell culture.
  • Stem cell exosomes contain complex components such as protein, insulin-like growth factor, epithelial cell growth factor, fibroblast growth factor, vascular epithelial cell growth factor, various fatty acids and antioxidants to help stem cell adhesion and growth.
  • the present invention has developed a serum-free culture medium containing stem cell-derived exosomes that can minimize cell damage of stem cells and help adhesion and growth.
  • An object of the present invention is to isolate the exosomes that induce cell attachment and proliferation from human stem cells, and to provide a new serum-free medium composition for culturing cells containing exosomes in the basal medium. It is an object of the present invention to provide a serum-free medium composition for stem cell culture comprising extracting an exosome having the efficacy of stem cell proliferation and culture from human adipose stem cells and a mixture thereof.
  • an object of the present invention contains exosomes derived from human stem cells, which can minimize cell damage, aid in cell adhesion and growth, and induce and promote cell proliferation.
  • Serum medium composition is provided.
  • an object of the present invention can overcome the shortcomings of serum by using a medium in which exosomes are added instead of animal serum, and can be applied to serum-free medium composition for stem cell culture to culture stem cells without animal serum. And finally, to provide a method for culturing stem cells for cell therapy for clinical applications.
  • the present invention is to isolate the exosomes to induce cell adhesion and proliferation from human stem cells, animal serum replacement agent comprising the isolated exosomes, cell culture containing exosomes in the basal medium Serum-free medium composition, and a method for culturing cells using the same.
  • exosome refers to a membrane vesicle that is secreted from various cell types, and serves various roles such as delivering membrane components, proteins, and RNA to other cells and tissues. It is known.
  • the stem cells derived from exosomes may be adult stem cells, more specifically, may be selected from the group consisting of adipose derived stem cells, bone marrow stem cells and umbilical cord blood stem cells, Preferably, it may be selected from the group consisting of human adipose derived stem cells, human bone marrow stem cells, and human umbilical cord blood stem cells, and more preferably human adipose derived stem cells, but is not limited thereto.
  • the animal serum replacement agent and / or serum-free medium composition for cell culture of one embodiment of the present invention is preferably used for culturing animal cells, more preferably for culturing stem cells.
  • the serum-free medium composition for cell culture of one embodiment of the present invention is characterized in that it contains exosomes derived from human stem cells, preferably human fat-derived stem cells, as an active ingredient, and does not include animal serum.
  • Exosomes derived from human stem cells, preferably human adipose-derived stem cells are used by mixing in a basic medium at a constant rate to maximize the proliferation effect of animal cells, preferably stem cells.
  • human stem cell-derived exosomes isolated from serum-free, antibiotic-free medium contain growth factors effective for promoting growth and maintenance of various proliferation-related cells, such as cell activators or growth factors. It can be effectively applied as a serum-free medium composition for culturing animal cells, preferably stem cells, without additives. Therefore, the animal serum replacement agent and / or serum-free medium composition for cell culture of one embodiment of the present invention can culture animal cells, preferably stem cells, without animal serum.
  • basal medium' refers to a culture medium containing essential ingredients necessary for growth and proliferation of cells in vitro.
  • the basal medium may be artificially synthesized or commercially prepared medium.
  • DMEM Dulbecco's Modified Eagle's Medium
  • MEM Minimal Essential Medium
  • RPMI 1640 F-10, F-12
  • G-MEM Glasgow's Mineral Essential Medium
  • IMDM Iscove's Modified Dulbecco's Medium
  • the exosomes may be included in the medium at a concentration of 0.01 to 1,000 ⁇ g / mL.
  • the exosomes can be prepared using a conventional exosome separation method, for example
  • exosomes are not only loaded with genetic information, proteins, and growth factors of stem cells, but the exosomes themselves may serve as carriers.
  • Exosomes consisting of lipids of about 50-150 nm in size are biocompatible because they are cell-derived materials, and the uptake of cells is also very good.
  • a serum-free medium composition for cell culture containing such exosomes as an active ingredient promotes the attachment and proliferation of animal cells, preferably stem cells.
  • the serum-free medium composition for cell culture of one embodiment of the present invention can be used as a composition for stem cell culture for clinical application.
  • Another aspect of the invention is the step of separating the exosomes from human stem cells; Preparing a serum-free medium composition for cell culture comprising the isolated exosomes; And it provides a cell culture method comprising culturing the cells in the serum-free medium composition for cell culture.
  • the human stem cells may be selected from the group consisting of human adipose derived stem cells, human bone marrow stem cells and human umbilical cord blood stem cells, more preferably human adipose derived stem cells It may be, but is not limited thereto.
  • the serum-free medium composition for cell culture is preferably used for the culturing of animal cells, more preferably for the culturing of stem cells derived from exosomes.
  • the cell culture-free serum medium composition is characterized in that it does not contain animal serum.
  • the cell culture-free serum medium composition is characterized in that it contains substantially no animal serum.
  • the term “substantially free of” may be completely devoid of the component, or contain little of the component to the extent that the effect may be the same as if the component was completely lacking. In other words, a composition that is "substantially free” of components or elements may still actually contain these items unless there is a measurable effect thereof.
  • the term “substantially free of” refers to up to 5 wt%, up to 4 wt%, up to 3 wt% or up to 2 wt%, preferably up to 1 wt%, more preferably 0.1, based on the total content of the composition unless otherwise indicated. It may mean up to weight percent, even more preferably up to 0.01 weight percent.
  • Animal serum substitutes comprising exosomes derived from human stem cells of the present invention, and serum-free medium composition for cell culture containing the same contains genes, proteins, growth factors, etc., which are related to cell growth, and thus cell activators or growth factors. Without other additives, it can help cells attach and grow and induce cell proliferation.
  • Human stem cell-derived exosomes used in the present invention can overcome the problems of animal serum because it is a purified component that does not contain antibiotics, serum, or harmful eyeballs of the culture medium, cell penetration and effective factors because of cell-derived lipid transporter The transmission efficiency is very good.
  • the present invention can overcome the shortcomings of the serum by using a medium in which exosomes are added instead of animal serum, and can be applied to a serum-free medium composition for stem cell culture, thereby culturing stem cells without animal serum. Finally, it can be used for culturing stem cells for cell therapy for clinical applications.
  • Figure 1 shows the results for the characterization of exosomes produced from human adipose derived stem cells
  • Figure 1a is the concentration of stem cell exosomes confirmed using a nanoparticle tracking analysis (Nanoparticle Tracking Analysis, NTA),
  • Figure 1b is the form of stem cell exosomes confirmed using a transmission electron microscope (Transparent Electron Microscope, TEM), and
  • the scale bar of the image is 100 nm (black) and 20 nm (white), respectively.
  • Figure 2 shows the results of the cell proliferation evaluation of human adipose derived stem cells according to the exosome concentration.
  • Cell proliferation was evaluated by incubating human adipose derived stem cells (ASC, 1 ⁇ 10 4 cell / well) for 3 days in a 48-well plate, and the degree of cell proliferation was determined by CCK-8 reagent (Dojindo, cat no. DJB4000X) was used for absorbance analysis.
  • CCK-8 reagent Dojindo, cat no. DJB4000X
  • Exo-proliferation efficiency than some containing the cultured cells in serum-free medium resulting positive control (growth medium) is natatjiman, it was confirmed that the growth rate is improved as compared to the negative control (serum-free medium, SFM) in all experimental groups (P ⁇ 0.001).
  • stem cells cultured in a medium containing 50 ⁇ g / mL of exosomes were confirmed to improve cell growth efficiency more than two times compared to the negative control group
  • Figure 3 shows the results of evaluating the cell proliferation induction of exosomes in culture medium containing a low concentration of serum (Serum 1%, 3%, 5%).
  • Culture medium was prepared by adding 50 ⁇ g / mL of exosomes to all culture conditions except for positive control (Serum 10%).
  • ASC Human adipose derived stem cells
  • n Human adipose derived stem cells
  • Figure 4 shows the results of the differentiation effect of stem cells cultured in a serum-free medium containing exosomes to adipocytes.
  • (a) is an optical micrograph of human adipose derived stem cells cultured in a normal culture medium and a serum-free medium containing exosomes
  • (b) is a fat cell induced differentiation induced through differentiation induction medium in (a) It is an optical microscope photograph evaluated for differentiation ability by red O staining. Scale bars are 200 ⁇ m (white) and 50 ⁇ m (black) respectively. Evaluation of differentiation ability into adipocytes confirmed that the differentiation function of stem cells cultured in serum-free medium containing exosomes was well maintained.
  • Human adipose stem cell-derived exosomes were extracted during the process of culturing human adipose stem cells.
  • human adipose stem cells (Company: CellBio, Cat #: CB-ADMSC-001) are DMEM (Dulbecco) containing 10% FBS (fetal bovine serum) and 1% penicillin / streptomycin (penicillin / streptomycin). Modified Eagle Medium high glucose; Gibco, Cat #: 11995065). 24 hours before extracting the exosomes, the cells were replaced with serum-free, antibiotic-free, phenol-free medium (Company: Gibco, Cat #: 31053028) and cultured for 24 hours, and then cell culture supernatants were recovered. After the supernatant was recovered, normal culture medium was added to the stem cells and cultured. This process was repeated until passage 7.
  • DMEM Dulbecco
  • FBS fetal bovine serum
  • penicillin / streptomycin penicillin / streptomycin
  • Modified Eagle Medium high glucose Gibco, Cat #: 11995065
  • the recovered cell culture supernatant was centrifuged at 2,000 ⁇ g, 4 ° C. for 5 minutes, primary filtering step using a cell strainer (pore size; 40 ⁇ m), and a bottle top filter (pore size). ; 0.22 ⁇ m) to remove cell debris and wastes by a second filtering step.
  • tangential flow filtration THF was used for exosome enrichment and further purification.
  • the filter specification used was MWCO 300 kDa (Molecular Weight Cut-Off).
  • the exosomes extracted in the process of proliferation were used as the stem cell culture additive composition.
  • Exosomes extracted from human adipose derived stem cells of Example 1 were exosomes using a nanoparticle tracking analysis (NTA), a transmission electron microscope (TEM), and a flow cytometry. The concentration and purity of, size, morphology and CD surface markers were confirmed ( Figure 1).
  • exosomes are measured by performing sample dilution (dilution solution; 1X phosphate buffer saline (PBS) solution) so that the number of nanoparticles identified on the screen per frame can be within the range of 30 to 40 (FIG. 1A).
  • the exosome sample was treated with 1% phosphotungstic acid solution for 1 minute and subjected to negative staining. As a result, spherical nanoparticle morphology was observed, and the average particle size was about 100 nm (FIG. 1B).
  • CD9, CD63, and CD81 known as exosome membrane surface markers
  • flow rate analyzer After attaching the reagent (SBI, CD9 / 63 / 81-EXO FLOW Capture kit) and the fluorescent marker to which the surface marker specific antibody is bound to the magnetic bead on the surface of the exosome, the expression of the surface marker of the exosome was measured using a flow rate analyzer. It was confirmed (FIG. 1C).
  • Serum-free culture medium containing exosomes was prepared by mixing as shown in Table 1 below.
  • GM group Stem cell proliferation medium
  • SFM group fetal bovine serum 10%, penicillin / streptomycin 1%) for positive control group
  • SFM group serum-free medium
  • Example 2 Increasing the induction of cell proliferation of human adipose derived stem cells by adding 50 ⁇ g / mL of the exosomes isolated in Example 1 to a culture medium containing low serum, specifically 1%, 3%, and 5% serum Evaluation was performed (Table 2, FIG. 3).
  • GM group human adipose derived stem cells
  • SFM group serum-free medium
  • human adipose derived stem cells (ASC, 1 ⁇ 10 4 cell / well) are radish containing proliferation medium (DMEM + FBS 10% + P / S 1%) and exosomes.
  • DMEM Dulbecco Modified Eagle Medium high glucose; Gibco, Cat #: 11995065
  • FBS fetal bovine serum
  • IBMX Isobutyl-1-methylxanthine; Sigma, Cat # I5879-1G
  • 10 ⁇ g / mL Insulin Sigma, Cat # I16634-100
  • 1 ⁇ M Dexamethasone Abcam, Cat # ab12074
  • 100 ⁇ M Indomethacin Sigma, Cat # I7378-5
  • exosomes produced from human adipose derived stem cells were found to be effective ingredients that help cell proliferation while maintaining the differentiation ability of human adipose derived stem cells.

Abstract

The present invention provides a novel serum-free medium composition for culturing cells, wherein an exosome that induces cell adhesion and proliferation is separated from a human stem cell, and the exosome is contained in a basic medium. A serum-free medium composition for culturing cells according to the present invention contains genes, proteins, and growth factors related to cell growth, and thus can assist cell adhesion and growth even without other additives such as cell activators or growth factors, and can induce and promote cell proliferation. The present invention can minimize the disadvantages of serum by using a medium in which an exosome is added instead of animal serum, or by minimizing the amount of serum used, and can ultimately be used in the culturing of stem cells for cell therapy for clinical application.

Description

인간줄기세포 유래 엑소좀을 포함하는 세포 배양용 무혈청 배지 조성물Serum-free medium composition for cell culture comprising human stem cell-derived exosomes
본 출원은 2017년 6월 7일 출원된 대한민국출원 제10-2017-0070592호에 기초한 우선권을 주장하며, 해당 출원의 명세서 및 도면에 개시된 모든 내용은 본 출원에 원용된다.This application claims priority based on Korean Patent Application No. 10-2017-0070592 filed on June 7, 2017, and all the contents disclosed in the specification and drawings of the application are incorporated in this application.
본 발명은 인간줄기세포로부터 유래된 엑소좀을 유효성분으로 함유하는 세포 배양용 무혈청 배지 조성물에 관한 것으로, 보다 상세하게는 인간줄기세포로부터 유래된 엑소좀을 함유하여, 세포손상을 최소화할 수 있고 세포의 부착 및 성장에 도움을 주며 세포 증식을 유도·촉진시킬 수 있는 새로운 세포 배양용 무혈청 배지 조성물에 관한 것이다.The present invention relates to a serum-free medium composition for culturing cells containing exosomes derived from human stem cells as an active ingredient, more specifically, containing exosomes derived from human stem cells, it is possible to minimize cell damage And a new serum-free medium composition for cell culture that can aid in cell adhesion and growth and induce and promote cell proliferation.
또한, 본 발명은 인간줄기세포로부터 유래된 엑소좀을 포함하는 동물혈청 대체제, 이를 함유하는 세포 배양용 무혈청 배지 조성물, 및 이들을 이용하여 세포를 배양하는 방법에 관한 것이다.The present invention also relates to an animal serum replacement agent comprising an exosome derived from human stem cells, a serum-free medium composition for cell culture containing the same, and a method of culturing cells using the same.
추가로, 본 발명은 동물 혈청 대신 엑소좀이 첨가된 배지를 사용하여 혈청의 단점을 극복할 수 있고, 줄기세포 배양용 무혈청 배지 조성물로의 적용이 가능하여 동물 혈청 없이도 줄기세포를 배양할 수 있으며, 최종적으로는 임상 적용을 위한 세포 치료용 줄기세포를 배양할 수 있는 방법에 관한 것이다.In addition, the present invention can overcome the shortcomings of the serum by using a medium in which exosomes are added instead of animal serum, and can be applied to a serum-free medium composition for stem cell culture, thereby culturing stem cells without animal serum. And finally to a method for culturing stem cells for cell therapy for clinical applications.
혈청에는 세포의 성장과 기능을 촉진하는 인슐린 또는 폴리펩티드 계통의 다양한 호르몬과 세포의 분열과 기능을 조절하는 성장 인자들, 그리고 피브로넥틴과 같은 부착 및 확산 인자들, 결합 단백질로 트랜스페린이 있으며, 지질, 무기질 등 미량 요소들이 다수 포함되어 있다. 혈청은 또한 완충액으로서 배양액의 삼투압과 pH를 조절하며, 단백질 분해 저해 및 물리적 충격에서 세포를 보호할 수 있는 점성 작용도 가지고 있다. 이처럼 다양한 기능을 가진 물질들이 포함된 혈청을 사용하여 세포를 배양할 수 있다.Serum contains a variety of hormones in the insulin or polypeptide family that promote cell growth and function, growth factors that regulate cell division and function, and adhesion and diffusion factors such as fibronectin, transferrin as a binding protein, lipids and minerals. Many trace elements are included. Serum is also a buffer that regulates the osmotic pressure and pH of the culture, and has a viscous action that protects cells from proteolytic inhibition and physical shock. Cells can be cultured using serum containing these various functions.
줄기세포는 미분화 상태에서 일정기간 동안 자신과 동일한 세포를 지속적으로 만들어 낼 수 있는 성질과 적당한 조건하에서는 특정한 세포로 분화하는 성질을 가지고 있다. 성체 줄기세포는 골수, 혈액, 뇌, 피부, 지방 등에서 얻을 수 있으며 여러 조직 세포로 분화가 가능한 것으로 알려져 있다. 특히 지방유래 줄기세포(adipose derived stem cell), 골수유래 중간엽줄기세포(Bone marrow derived stem cell), 제대 혹은 제대혈유래 줄기세포(umbilical- or umbilical-cord blood derived stem cell)와 같은 성체줄기세포는 자가 혹은 타가 세포치료제로의 개발에 대한 연구도 활발히 진행되고 있다.Stem cells have the property of continuously producing the same cells as themselves for a certain period of time in an undifferentiated state, and differentiate into specific cells under suitable conditions. Adult stem cells can be obtained from bone marrow, blood, brain, skin, and fat, and are known to be able to differentiate into various tissue cells. In particular, adult stem cells such as adipose derived stem cells, bone marrow derived stem cells, umbilical cord or umbilical-cord blood derived stem cells Research into the development of autologous or other cell therapy is also actively underway.
그러나, 이러한 인간줄기세포를 배양하기 위해 동물혈청을 함유하는 배지를 이용하는 경우, 임상 적용 전 동물혈청이 없는 용액으로 세척하더라도 상당량의 동물혈청이 세포내 잔류하여 강력한 이종항원으로 작용하며, 동물의 병원성 또는 기타 요인에 감염될 가능성이 매우 높다. 또한 동물혈청은 채취 시기와 채취 장소에 따라 성분의 변화가 있을 수 있어 혈청 함유 배지에서 배양된 줄기세포를 환자에게 투여하기에는 어려움이 있다.However, in the case of using a medium containing animal serum to culture such human stem cells, even if washed with a solution without animal serum before clinical application, a significant amount of animal serum remains in the cell acting as a strong heterologous antigen, animal pathogenicity Or other factors are very likely. In addition, animal serum may have a change in composition depending on the time and place of collection, it is difficult to administer to the patient stem cells cultured in a serum-containing medium.
이를 극복하기 위해 다양한 줄기세포 배양액이 개발되고 있다. 종래 세포배양배지에서 동물혈청 대신에 인간혈청을 사용하는 시도가 있으나, 인간혈청의 경우 공급원이 제한될 뿐 아니라 바이러스와 기타 감염 위험을 배제할 수 없어 실제로 임상 적용을 위한 줄기세포배양에 사용되지는 못하고 매우 제한적인 연구에서만 특정 목적으로 사용되고 있다. 최근에는 무혈청 배지에서 줄기세포를 배양하기 위한 다양한 방법들이 시도되고 있다. 그중 혈청 분할 방법(serum halving method)은 배지에 함유된 혈청의 농도를 점점 낮추어 최종적으로는 무혈청으로 세포를 배양하는 방법이다. 하지만 이 방법은 세포 증식에 어려움이 있고 세포 사멸(apotosis)로 진행될 가능성이 높으며 시간이 오래 걸리는 단점이 있어 환자에 투여할 줄기세포를 준비하는데 어려움이 있다.To overcome this, various stem cell cultures have been developed. Conventional cell culture media have attempted to use human serum instead of animal serum, but human serum is not used for stem cell culture for clinical applications because its source is limited and the risk of viruses and other infections cannot be excluded. Only very limited research is used for specific purposes. Recently, various methods for culturing stem cells in serum-free medium have been tried. Among them, the serum halving method is a method of gradually lowering the concentration of serum contained in the medium and finally culturing the cells in serum-free. However, this method has difficulty in proliferating cells, is likely to progress to apoptosis, and takes a long time, thus preparing a stem cell for administration to a patient.
현재 혈청 대신에 호르몬이나 성장 인자들 또는 정제 단백질을 첨가하여 줄기세포를 배양하는 방법이 가장 많이 사용되고 있다. 아미노산, 비타민, 인슐린 유사인자, 상피세포 성장인자, 섬유아세포 성장인자, 단백질 분해효소 억제제, 단백질, 셀레늄 등 줄기세포의 부착과 성장에 필요한 성분을 조합하여 기본 배지에 첨가하여 사용하고 있으나, 재조합 단백질 및 성장인자의 경우 매우 고가에 판매가 되고 있어 여러 가지 성분을 조합하여 사용하기에 어려움이 있다.Currently, the method of culturing stem cells by adding hormones, growth factors or purified proteins instead of serum is most commonly used. Although it is added to the basic medium by combining components necessary for adhesion and growth of stem cells such as amino acids, vitamins, insulin-like factors, epidermal growth factor, fibroblast growth factor, protease inhibitors, proteins and selenium, And growth factors are sold at a very high price, it is difficult to use a combination of various components.
한편, 인간을 포함한 다세포 생명체 내에 존재하는 다양한 세포에서는 '엑소좀'이라는 나노 크기의 소포체를 분비하는 것으로 알려졌다. 엑소좀은 세포막과 동일한 막 구조의 소낭체로, 다른 세포 및 조직에 막 구성요소, 단백질, RNA 등을 전달하는 역할을 하는 것으로 알려져 있다. 특히 줄기세포에서 분비되는 엑소좀은 줄기세포가 분비하는 다양한 성장인자와 사이토카인을 함유하고 있어, 세포의 부착, 성장, 분화 등의 거동을 조절한다고 알려져 있다. 또한 엑소좀은 분리하는 과정에서 세포 배양액 내 세포 노폐물, 항생제, 혈청 등 불순물이 제거되므로, 세포 배양액의 효과와 동등하면서 안전하게 사용 가능하다.On the other hand, it is known that various cells existing in multicellular organisms, including humans, secrete nanosized vesicles called exosomes. Exosomes are vesicles with the same membrane structure as cell membranes and are known to deliver membrane components, proteins, RNA, and the like to other cells and tissues. In particular, exosomes secreted from stem cells contain various growth factors and cytokines secreted by stem cells, and are known to regulate cell adhesion, growth, and differentiation. In addition, since exosomes are removed impurities such as cell waste, antibiotics, serum in the cell culture in the separation process, it can be used safely and equivalent to the effect of the cell culture.
줄기세포 엑소좀에는 단백질, 인슐린 유사 성장인자, 상피세포 성장인자, 섬유아세포 성장인자, 혈관상피세포 성장인자, 각종 지방산, 항산화제 등 복합 성분이 함유되어 있어 줄기세포의 부착 및 성장을 돕는다.Stem cell exosomes contain complex components such as protein, insulin-like growth factor, epithelial cell growth factor, fibroblast growth factor, vascular epithelial cell growth factor, various fatty acids and antioxidants to help stem cell adhesion and growth.
따라서, 본 발명에서는 줄기세포의 세포손상을 최소화할 수 있고 부착 및 성장에 도움을 주는 줄기세포 유래 엑소좀을 함유하는 무혈청 배양 배지를 개발하였다.Therefore, the present invention has developed a serum-free culture medium containing stem cell-derived exosomes that can minimize cell damage of stem cells and help adhesion and growth.
본 발명의 목적은 인간줄기세포로부터 세포 부착 및 증식을 유도하는 엑소좀을 분리하고, 기본 배지에 엑소좀이 함유된 새로운 세포 배양용 무혈청 배지 조성물을 제공하는 것이다. 본 발명의 목적은 인간지방줄기세포로부터 줄기세포 증식 및 배양의 효능을 지닌 엑소좀을 추출하고 이들의 혼합물을 포함하는 줄기세포 배양용 무혈청 배지 조성물을 제공하는 것이다.An object of the present invention is to isolate the exosomes that induce cell attachment and proliferation from human stem cells, and to provide a new serum-free medium composition for culturing cells containing exosomes in the basal medium. It is an object of the present invention to provide a serum-free medium composition for stem cell culture comprising extracting an exosome having the efficacy of stem cell proliferation and culture from human adipose stem cells and a mixture thereof.
구체적으로, 본 발명의 목적은 인간줄기세포로부터 유래된 엑소좀을 함유하여, 세포손상을 최소화할 수 있고 세포의 부착 및 성장에 도움을 주며 세포 증식을 유도·촉진시킬 수 있는 새로운 세포 배양용 무혈청 배지 조성물을 제공하는 것이다.Specifically, an object of the present invention contains exosomes derived from human stem cells, which can minimize cell damage, aid in cell adhesion and growth, and induce and promote cell proliferation. Serum medium composition is provided.
또한, 본 발명의 목적은 인간줄기세포로부터 유래된 엑소좀을 포함하는 동물 혈청 대체제, 이를 함유하는 세포 배양용 무혈청 배지 조성물, 및 이들을 이용하여 세포를 배양하는 방법을 제공하는 것이다.It is also an object of the present invention to provide an animal serum replacement agent comprising an exosome derived from human stem cells, a serum-free medium composition for cell culture containing the same, and a method of culturing cells using the same.
추가로, 본 발명의 목적은 동물 혈청 대신 엑소좀이 첨가된 배지를 사용하여 혈청의 단점을 극복할 수 있고, 줄기세포 배양용 무혈청 배지 조성물로의 적용이 가능하여 동물 혈청 없이도 줄기세포를 배양할 수 있으며, 최종적으로는 임상 적용을 위한 세포 치료용 줄기세포를 배양할 수 있는 방법을 제공하는 것이다.In addition, an object of the present invention can overcome the shortcomings of serum by using a medium in which exosomes are added instead of animal serum, and can be applied to serum-free medium composition for stem cell culture to culture stem cells without animal serum. And finally, to provide a method for culturing stem cells for cell therapy for clinical applications.
그러나, 전술한 바와 같은 본 발명의 과제는 예시적인 것으로, 이에 의해 본 발명의 범위가 제한되는 것은 아니다. However, the problems of the present invention as described above are exemplary, and the scope of the present invention is not limited thereby.
상기와 같은 목적을 달성하기 위하여, 본 발명은 인간줄기세포로부터 세포부착 및 증식을 유도하는 엑소좀을 분리하고, 분리된 엑소좀을 포함하는 동물혈청 대체제, 기본 배지에 엑소좀이 함유된 세포 배양용 무혈청 배지 조성물, 및 이들을 이용하여 세포를 배양하는 방법을 제공한다.In order to achieve the above object, the present invention is to isolate the exosomes to induce cell adhesion and proliferation from human stem cells, animal serum replacement agent comprising the isolated exosomes, cell culture containing exosomes in the basal medium Serum-free medium composition, and a method for culturing cells using the same.
본 발명의 명세서에서 사용되는 용어, "엑소좀(exosome)"이란 여러 종류의 세포들로부터 분비되는 막 구조의 소낭체로, 다른 세포 및 조직에 막 구성요소, 단백질, RNA를 전달하는 등 다양한 역할을 하는 것으로 알려져 있다.As used herein, the term “exosome” refers to a membrane vesicle that is secreted from various cell types, and serves various roles such as delivering membrane components, proteins, and RNA to other cells and tissues. It is known.
본 발명의 일 구체예에 있어서, 엑소좀이 유래되는 줄기세포는 성체 유래 줄기세포일 수 있으며, 보다 구체적으로는 지방유래 줄기세포, 골수 줄기세포 및 제대혈 줄기세포로 이루어진 군에서 선택될 수 있고, 바람직하게는 인간지방 유래 줄기세포, 인간 골수 줄기세포 및 인간 제대혈 줄기세포로 이루어진 군에서 선택될 수 있으며, 보다 바람직하게는 인간지방 유래 줄기세포일 수 있으나, 이에 제한되지 않는다.In one embodiment of the present invention, the stem cells derived from exosomes may be adult stem cells, more specifically, may be selected from the group consisting of adipose derived stem cells, bone marrow stem cells and umbilical cord blood stem cells, Preferably, it may be selected from the group consisting of human adipose derived stem cells, human bone marrow stem cells, and human umbilical cord blood stem cells, and more preferably human adipose derived stem cells, but is not limited thereto.
본 발명의 일 구체예의 동물혈청 대체제 및/또는 세포 배양용 무혈청 배지 조성물은 바람직하게는 동물세포의 배양에 사용되고, 더욱 바람직하게는 줄기세포의 배양에 사용될 수 있다.The animal serum replacement agent and / or serum-free medium composition for cell culture of one embodiment of the present invention is preferably used for culturing animal cells, more preferably for culturing stem cells.
본 발명의 일 구체예의 세포 배양용 무혈청 배지 조성물은 인간줄기세포, 바람직하게는 인간지방 유래 줄기세포에서 유래된 엑소좀을 유효성분으로 함유하고, 동물 혈청을 포함하지 않는 것을 특징으로 한다. 인간줄기세포, 바람직하게는 인간지방 유래 줄기세포에서 유래된 엑소좀은 동물세포, 바람직하게는 줄기세포의 증식효과가 극대화될 수 있도록 일정한 비율로 기본 배지에 혼합하여 사용한다.The serum-free medium composition for cell culture of one embodiment of the present invention is characterized in that it contains exosomes derived from human stem cells, preferably human fat-derived stem cells, as an active ingredient, and does not include animal serum. Exosomes derived from human stem cells, preferably human adipose-derived stem cells are used by mixing in a basic medium at a constant rate to maximize the proliferation effect of animal cells, preferably stem cells.
본 발명의 일 구체예에 있어서, 무혈청, 무항생제 배지에서 분리된 인간줄기 세포 유래 엑소좀은 다양한 증식관련 세포들의 성장촉진 및 세포 유지에 유효한 성장인자를 함유하고 있어 세포 활성화제나 성장인자 같은 다른 첨가물 없이도 동물세포, 바람직하게는 줄기세포 배양용 무혈청 배지 조성물로 효과적으로 응용할 수 있다. 따라서, 본 발명의 일 구체예의 동물혈청 대체제 및/또는 세포 배양용 무혈청 배지 조성물은 동물 혈청 없이도 동물세포, 바람직하게는 줄기세포를 배양할 수 있다.In one embodiment of the present invention, human stem cell-derived exosomes isolated from serum-free, antibiotic-free medium contain growth factors effective for promoting growth and maintenance of various proliferation-related cells, such as cell activators or growth factors. It can be effectively applied as a serum-free medium composition for culturing animal cells, preferably stem cells, without additives. Therefore, the animal serum replacement agent and / or serum-free medium composition for cell culture of one embodiment of the present invention can culture animal cells, preferably stem cells, without animal serum.
본 발명의 명세서에서 사용되는 용어, '기본 배지'라 함은 생체외(in vitro)에서 세포의 성장과 증식에 필요한 필수성분을 포함하는 배양액을 말한다. 상기 기본 배지는 인위적으로 합성하거나 상업적으로 제조된 배지를 사용할 수 있다. As used herein, the term 'basal medium' refers to a culture medium containing essential ingredients necessary for growth and proliferation of cells in vitro. The basal medium may be artificially synthesized or commercially prepared medium.
상업적으로 제조된 배지는 예컨대, DMEM(Dulbecco's Modified Eagle's Medium), MEM(Minimal Essential Medium), RPMI 1640, F-10, F-12, α-MEM(α-Mineral Essential Medium: Gibco, Invitrogen, Newyork), G-MEM(Glasgow's Mineral Essential Medium), IMDM(Iscove's Modified Dulbecco's Medium) 등을 들 수 있다.Commercially prepared media include, for example, Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), RPMI 1640, F-10, F-12, α-Mineral Essential Medium: Gibco, Invitrogen, Newyork , Glasgow's Mineral Essential Medium (G-MEM), and Iscove's Modified Dulbecco's Medium (IMDM).
구체적으로, 상기 엑소좀은 0.01 내지 1,000 μg/mL의 농도로 배지에 포함될 수 있다.Specifically, the exosomes may be included in the medium at a concentration of 0.01 to 1,000 μg / mL.
한편, 상기 엑소좀은 통상적인 엑소좀 분리 방법을 이용하여 제조할 수 있고, 예를 들어On the other hand, the exosomes can be prepared using a conventional exosome separation method, for example
1) 줄기세포를 배양 배지에 배양한 다음 무혈청 및 무항생제 배지에서 계대 배양하는 단계;1) culturing the stem cells in the culture medium and then passage in serum-free and antibiotic-free medium;
2) 세포 배양 상층액을 회수하는 단계;2) recovering the cell culture supernatant;
3) 회수한 세포 배양 상층액을 원심분리하는 단계; 및3) centrifuging the recovered cell culture supernatant; And
4) 엑소좀을 분리 및 정제하는 단계에 의하여 제조될 수 있으나, 이에 한정되지 않는다.4) may be prepared by the step of separating and purifying the exosomes, but is not limited thereto.
상기 엑소좀은 줄기세포의 유전정보, 단백질, 성장인자가 담지되었을 뿐 아니라 엑소좀 자체가 전달체 역할까지 할 수 있다. 약 50-150 nm 크기의 지질로 이루어진 엑소좀은 세포 유래 물질이기 때문에 생체적합하며, 세포의 흡수율 또한 매우 좋다.The exosomes are not only loaded with genetic information, proteins, and growth factors of stem cells, but the exosomes themselves may serve as carriers. Exosomes consisting of lipids of about 50-150 nm in size are biocompatible because they are cell-derived materials, and the uptake of cells is also very good.
본 발명의 일 구체예의 동물혈청 대체제 및/또는 세포 배양용 무혈청 배지 조성물에 포함된 인간줄기세포 유래 엑소좀은 항생제나 혈청, 배양액의 유해 인자들이 포함되지 않은 정제된 성분이기 때문에 동물 혈청의 문제점을 극복할 수 있으며, 세포 유래 지질 전달체이기 때문에 세포 침투 및 유효인자 전달 효율이 매우 뛰어나다. 이러한 엑소좀을 유효성분으로 함유하는 세포 배양용 무혈청 배지 조성물은 동물세포, 바람직하게는 줄기세포의 부착 및 증식을 촉진시킨다.Problems of animal serum because human stem cell-derived exosomes contained in the animal serum replacement agent and / or serum-free medium composition for cell culture of one embodiment of the present invention are purified components that do not contain antibiotics, serum, or harmful factors of the culture solution. It is possible to overcome this, and because it is a cell-derived lipid transporter, the cell penetration and effective factor delivery efficiency is very excellent. A serum-free medium composition for cell culture containing such exosomes as an active ingredient promotes the attachment and proliferation of animal cells, preferably stem cells.
따라서, 본 발명의 일 구체예의 세포 배양용 무혈청 배지 조성물은 임상적용을 위한 줄기세포 배양용 조성물로 사용할 수 있다.Therefore, the serum-free medium composition for cell culture of one embodiment of the present invention can be used as a composition for stem cell culture for clinical application.
본 발명의 다른 측면은 인간줄기세포로부터 엑소좀을 분리하는 단계; 분리된 엑소좀을 포함하는 세포 배양용 무혈청 배지 조성물을 준비하는 단계; 및 세포를 상기 세포 배양용 무혈청 배지 조성물에서 배양하는 단계를 포함하는 세포 배양 방법을 제공한다.Another aspect of the invention is the step of separating the exosomes from human stem cells; Preparing a serum-free medium composition for cell culture comprising the isolated exosomes; And it provides a cell culture method comprising culturing the cells in the serum-free medium composition for cell culture.
본 발명의 일 구체예의 세포 배양 방법에 있어서, 상기 인간줄기세포는 인간 지방 유래 줄기세포, 인간 골수 줄기세포 및 인간 제대혈 줄기세포로 이루어진 군에서 선택될 수 있으며, 보다 바람직하게는 인간지방 유래 줄기세포일 수 있으나, 이에 제한되지 않는다.In the cell culture method of an embodiment of the present invention, the human stem cells may be selected from the group consisting of human adipose derived stem cells, human bone marrow stem cells and human umbilical cord blood stem cells, more preferably human adipose derived stem cells It may be, but is not limited thereto.
본 발명의 일 구체예의 세포 배양 방법에 있어서, 상기 세포 배양용 무혈청 배지 조성물은 바람직하게는 동물세포의 배양에 사용되고, 더욱 바람직하게는 엑소좀과 같은 유래의 줄기세포의 배양에 사용될 수 있다.In the cell culture method of one embodiment of the present invention, the serum-free medium composition for cell culture is preferably used for the culturing of animal cells, more preferably for the culturing of stem cells derived from exosomes.
본 발명의 일 구체예의 세포 배양 방법에 있어서, 상기 세포 배양용 무혈청 배지 조성물은 동물 혈청을 포함하지 않는 것을 특징으로 한다.In the cell culture method of an embodiment of the present invention, the cell culture-free serum medium composition is characterized in that it does not contain animal serum.
또한 본 발명의 일 구체예에서, 상기 세포 배양용 무혈청 배지 조성물은 동물 혈청을 실질적으로 포함하지 않는 것을 특징으로 한다.In addition, in one embodiment of the present invention, the cell culture-free serum medium composition is characterized in that it contains substantially no animal serum.
용어 "실질적으로 포함하지 않는"은 해당 성분을 완전히 결여하거나, 또는 효과가 해당 성분이 완전히 결여된 경우와 동일한 수 있을 정도로 해당 성분을 거의 함유하지 않는 것일 수 있다. 다시 말해서, 성분 또는 요소를 "실질적으로 포함하지 않는" 조성물은 이의 측정가능한 효과가 없는 한 이러한 항목을 여전히 실제적으로 함유할 수 있다. 용어 "실질적으로 포함하지 않는"는 달리 나타내지 않는 한 조성물 총 함량 대비 5 중량% 이하, 4 중량% 이하, 3 중량% 이하 또는 2 중량% 이하, 바람직하게는 1 중량% 이하, 더욱 바람직하게는 0.1 중량% 이하, 보다 더 바람직하게는 0.01 중량% 이하를 의미할 수 있다.The term “substantially free of” may be completely devoid of the component, or contain little of the component to the extent that the effect may be the same as if the component was completely lacking. In other words, a composition that is "substantially free" of components or elements may still actually contain these items unless there is a measurable effect thereof. The term “substantially free of” refers to up to 5 wt%, up to 4 wt%, up to 3 wt% or up to 2 wt%, preferably up to 1 wt%, more preferably 0.1, based on the total content of the composition unless otherwise indicated. It may mean up to weight percent, even more preferably up to 0.01 weight percent.
본 발명의 인간줄기세포로부터 유래된 엑소좀을 포함하는 동물혈청 대체제 및 이를 함유하는 세포 배양용 무혈청 배지 조성물은 세포의 성장과 관련된 유전자, 단백질, 성장인자 등을 함유하고 있어 세포 활성화제나 성장인자 같은 다른 첨가물 없이도 세포의 부착 및 성장에 도움을 줄 수 있으며 세포 증식을 유도촉진 할 수 있다. 본 발명에서 사용되는 인간줄기세포 유래 엑소좀은 항생제나 혈청, 배양액의 유해 안자들이 포함되지 않은 정제된 성분이기 때문에 동물 혈청의 문제점을 극복할 수 있으며, 세포 유래 지질 전달체이기 때문에 세포 침투 및 유효인자 전달 효율이 매우 뛰어나다.Animal serum substitutes comprising exosomes derived from human stem cells of the present invention, and serum-free medium composition for cell culture containing the same contains genes, proteins, growth factors, etc., which are related to cell growth, and thus cell activators or growth factors. Without other additives, it can help cells attach and grow and induce cell proliferation. Human stem cell-derived exosomes used in the present invention can overcome the problems of animal serum because it is a purified component that does not contain antibiotics, serum, or harmful eyeballs of the culture medium, cell penetration and effective factors because of cell-derived lipid transporter The transmission efficiency is very good.
따라서, 본 발명은 동물 혈청 대신 엑소좀이 첨가된 배지를 사용하여 혈청의 단점을 극복할 수 있고, 줄기세포 배양용 무혈청 배지 조성물로의 적용이 가능하여 동물 혈청 없이도 줄기세포를 배양할 수 있으며, 최종적으로는 임상 적용을 위한 세포 치료용 줄기세포 배양에 사용될 수 있다. Therefore, the present invention can overcome the shortcomings of the serum by using a medium in which exosomes are added instead of animal serum, and can be applied to a serum-free medium composition for stem cell culture, thereby culturing stem cells without animal serum. Finally, it can be used for culturing stem cells for cell therapy for clinical applications.
한편, 전술한 바와 같은 효과들에 의해 본 발명의 범위가 제한되는 것은 아니다. On the other hand, the scope of the present invention is not limited by the effects as described above.
도면 1(도 1a 내지 1c)은 인간 지방유래 줄기세포로부터 생산된 엑소좀의 특성 분석에 대한 결과를 나타낸 것으로, Figure 1 (Fig. 1a to 1c) shows the results for the characterization of exosomes produced from human adipose derived stem cells,
도 1a는 나노입자추적분석기(Nanoparticle Tracking Analysis, NTA)를 이용하여 확인한 줄기세포 엑소좀의 농도, Figure 1a is the concentration of stem cell exosomes confirmed using a nanoparticle tracking analysis (Nanoparticle Tracking Analysis, NTA),
도 1b는 투과전자현미경(Transparent Electron Microscope, TEM)을 이용하여 확인한 줄기세포 엑소좀의 형태, 및 Figure 1b is the form of stem cell exosomes confirmed using a transmission electron microscope (Transparent Electron Microscope, TEM), and
도 1c는 유세포분석기(Flow cytometry)를 이용하여 엑소좀의 표면마커를 분석한 도이다 (n=3). 엑소좀의 특이적인 마커인 CD9, CD63, CD81이 각각 94.67%, 98.22%, 89.64% 발현하는 것을 확인하였다(n=5). 이미지의 스케일바(Scale bar)는 각각 100 nm(검은색)과 20 nm(흰색)이다.1c is a diagram of surface marker analysis of exosomes using flow cytometry (n = 3). CD9, CD63, and CD81, which are specific markers of exosomes, were found to express 94.67%, 98.22%, and 89.64%, respectively (n = 5). The scale bar of the image is 100 nm (black) and 20 nm (white), respectively.
도면 2는 엑소좀 농도에 따른 인간 지방유래 줄기세포의 세포증식 평가를 실시한 결과를 나타낸 것이다. 세포의 증식 평가는 인간 지방유래 줄기세포(ASC, 1×104 cell/well)를 48-웰 플레이트(well plate)에서 3일간 배양하고, 세포 증식정도를 CCK-8 시약(Dojindo, cat no. DJB4000X)을 통해 흡광도 분석하여 실시하였다. 엑소좀이 함유된 무혈청배지에서 세포를 배양한 결과 양성대조군(growth medium) 보다는 증식효율이 낮았지만, 모든 실험군에서 음성대조군(serum-free medium, SFM)에 비해서는 증식률이 향상된 것을 확인하였다(P < 0.001). 특히 50 ㎍/mL의 엑소좀을 함유한 배지에서 배양된 줄기세포는 음성대조군에 비해 2배 이상 세포증식 효율이 향상됨을 확인하였다.Figure 2 shows the results of the cell proliferation evaluation of human adipose derived stem cells according to the exosome concentration. Cell proliferation was evaluated by incubating human adipose derived stem cells (ASC, 1 × 10 4 cell / well) for 3 days in a 48-well plate, and the degree of cell proliferation was determined by CCK-8 reagent (Dojindo, cat no. DJB4000X) was used for absorbance analysis. Exo-proliferation efficiency than some containing the cultured cells in serum-free medium resulting positive control (growth medium) is natatjiman, it was confirmed that the growth rate is improved as compared to the negative control (serum-free medium, SFM) in all experimental groups (P <0.001). In particular, stem cells cultured in a medium containing 50 μg / mL of exosomes were confirmed to improve cell growth efficiency more than two times compared to the negative control group.
도면 3은 낮은 농도의 혈청(Serum 1%, 3%, 5%)이 함유된 배양배지에서 엑소좀의 세포증식 유도능을 평가한 결과를 나타낸 것이다. 양성대조군(Serum 10%)을 제외한 모든 배양 조건에 50 μg/mL의 엑소좀을 첨가하여 배양배지를 조성하였다. 인간 지방유래 줄기세포(ASC, 1×104 cell/well)는 각각 48-웰 플레이트(well plate)에서 3일간 배양하면서 평가하였다(n=5). (a)는 각각 다른 조성의 배양배지에서 세포증식률을 나타낸 그래프이고, (b)는 (a) 그래프의 값들을 수치화한 표이다. 양성대조군을 제외한 모든 실험군에서 엑소좀을 처리한 배양배지에서 배양된 줄기세포가 평균적으로 1.5배 이상 증식율이 향상되는 것을 확인하였다(P < 0.001).Figure 3 shows the results of evaluating the cell proliferation induction of exosomes in culture medium containing a low concentration of serum (Serum 1%, 3%, 5%). Culture medium was prepared by adding 50 μg / mL of exosomes to all culture conditions except for positive control (Serum 10%). Human adipose derived stem cells (ASC, 1 × 10 4 cell / well) were evaluated by incubating for 3 days in 48-well plates (n = 5), respectively. (a) is a graph showing the cell proliferation rate in each culture medium of different composition, (b) is a table quantifying the values of the (a) graph. In all experimental groups except the positive control group, it was confirmed that the stem cells cultured in the exosome-treated culture medium improved the proliferation rate by 1.5 times or more ( P <0.001).
도면 4는 엑소좀이 포함된 무혈청배지에서 배양된 줄기세포의 지방세포로의 분화효능 결과를 나타낸 것이다. 줄기세포의 분화 효능 평가는 인간 지방유래 줄기세포(ASC, 1×104 cell/well)를 24-웰 플레이트(well plate)에서 증식배지(DMEM + FBS 10% + P/S 1%)와 엑소좀이 함유된 무혈청배지(DMEM + 50 μg/mL의 엑소좀)에서 3일간 배양하여 세포밀도를 높인 다음, 지방세포(adipocyte) 분화 유도용 배지로 교체하여 2주 동안 분화유도 실시하였다(n=3). (a)는 일반 배양배지와 엑소좀이 함유된 무혈청배지에서 배양된 인간 지방유래 줄기세포의 광학현미경 사진이고, (b)는 (a)에서 분화유도배지를 통해 분화 유도된 지방세포를 Oil red O 염색하여 분화능 평가한 광학현미경 사진이다. 스케일바(Scale bar)는 각각 200 μm(흰색)과 50 μm(검은색)이다. 지방세포로의 분화능 평가를 통해 엑소좀이 함유된 무혈청배지에서 배양된 줄기세포의 분화기능이 잘 유지된 것을 확인하였다. Figure 4 shows the results of the differentiation effect of stem cells cultured in a serum-free medium containing exosomes to adipocytes. Evaluation of differentiation efficacy of stem cells was carried out in the growth of human adipose derived stem cells (ASC, 1 × 10 4 cells / well) in 24-well plates (DMEM + FBS 10% + P / S 1%) and exo Cell density was increased by culturing in serum-free medium (DMEM + 50 μg / mL exosomes) for 3 days to increase cell density, and then changed into an adipocyte differentiation-inducing medium for differentiation oil for 2 weeks (n = 3). (a) is an optical micrograph of human adipose derived stem cells cultured in a normal culture medium and a serum-free medium containing exosomes, (b) is a fat cell induced differentiation induced through differentiation induction medium in (a) It is an optical microscope photograph evaluated for differentiation ability by red O staining. Scale bars are 200 μm (white) and 50 μm (black) respectively. Evaluation of differentiation ability into adipocytes confirmed that the differentiation function of stem cells cultured in serum-free medium containing exosomes was well maintained.
이하 본 발명을 하기 실시 예에서 보다 상세하게 기술한다. 다만, 하기 실시예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 권리범위를 제한하거나 한정하는 것이 아니다. 본 발명의 상세한 설명 및 실시예로부터 본 발명이 속하는 기술분야의 통상의 기술자가 용이하게 유추할 수 있는 것은 본 발명의 권리범위에 속하는 것으로 해석된다. 본 발명에 인용된 참고문헌들은 본 발명에 참고로서 통합된다.Hereinafter, the present invention will be described in more detail in the following examples. However, the following examples merely illustrate the contents of the present invention and do not limit or limit the scope of the present invention. From the detailed description and examples of the present invention, those skilled in the art to which the present invention pertains can be easily inferred to be within the scope of the present invention. References cited in the present invention are incorporated herein by reference.
<실시예 1> 인간 지방유래 줄기세포로부터 엑소좀 분리Example 1 Isosome Isolation from Human Adipose Stem Cells
인간지방 줄기세포유래 엑소좀은 인간지방줄기세포를 배양하는 과정에서 추출하였다.Human adipose stem cell-derived exosomes were extracted during the process of culturing human adipose stem cells.
구체적으로, 인간지방줄기세포(업체: 세포바이오, Cat#: CB-ADMSC-001)는 10% FBS(fetal bovine serum) 및 1% 페니실린/스트렙토마이신(penicillin/streptomycin)가 포함되어 있는 DMEM(Dulbecco Modified Eagle Medium high glucose; Gibco, Cat#: 11995065) 배양 배지에서 배양하였다. 엑소좀을 추출하기 24시간 전에 무혈청, 무항생제, 무페놀레드인 배지(업체: Gibco, Cat#: 31053028)로 교체하여 24시간 동안 배양한 후, 세포 배양 상층액을 회수하였다. 상층액을 회수한 이후에는 다시 일반 배양배지를 줄기세포에 첨가하여 배양하였고, 이러한 과정은 계대 7까지 반복하였다. Specifically, human adipose stem cells (Company: CellBio, Cat #: CB-ADMSC-001) are DMEM (Dulbecco) containing 10% FBS (fetal bovine serum) and 1% penicillin / streptomycin (penicillin / streptomycin). Modified Eagle Medium high glucose; Gibco, Cat #: 11995065). 24 hours before extracting the exosomes, the cells were replaced with serum-free, antibiotic-free, phenol-free medium (Company: Gibco, Cat #: 31053028) and cultured for 24 hours, and then cell culture supernatants were recovered. After the supernatant was recovered, normal culture medium was added to the stem cells and cultured. This process was repeated until passage 7.
회수한 세포배양 상층액은 2,000 ×g, 4 ℃에서 5분간 원심분리하는 단계와 셀 스트레이너(Cell strainer, 공극크기; 40 μm)를 이용한 일차 필터링 단계, 그리고 바틀탑 필터(Bottle top filter, 공극크기; 0.22 μm)를 이용한 이차 필터링 단계를 거쳐 세포 잔해물 및 노폐물을 제거해주었다. 1차 정제단계를 거친 다음, 엑소좀 농축 및 추가정제를 위해 접선유동여과 시스템(Tangential flow filtration; TFF)을 이용하였다. 이때, 사용한 필터규격은 MWCO 300 kDa(Molecular Weight Cut-Off)를 사용하였다.The recovered cell culture supernatant was centrifuged at 2,000 × g, 4 ° C. for 5 minutes, primary filtering step using a cell strainer (pore size; 40 μm), and a bottle top filter (pore size). ; 0.22 μm) to remove cell debris and wastes by a second filtering step. After the first purification step, tangential flow filtration (TFF) was used for exosome enrichment and further purification. At this time, the filter specification used was MWCO 300 kDa (Molecular Weight Cut-Off).
이렇게 증식시키는 과정에서 추출한 엑소좀을 줄기세포 배양액 첨가물 조성물로 이용하였다.The exosomes extracted in the process of proliferation were used as the stem cell culture additive composition.
<실시예 2> 인간 지방유래 줄기세포 엑소좀의 특성 분석Example 2 Characterization of Human Adipose-Derived Stem Cell Exosomes
실시예 1의 인간지방유래 줄기세포로부터 추출된 엑소좀을 나노입자추적분석기(Nanoparticle tracking analysis, NTA)와 투과전자현미경(Transmission electron microscope, TEM), 그리고 유세포분석기(Flow cytometry)를 이용하여 엑소좀의 농도와 순도, 크기, 형태 및 CD 표면 마커를 확인하였다(도 1). Exosomes extracted from human adipose derived stem cells of Example 1 were exosomes using a nanoparticle tracking analysis (NTA), a transmission electron microscope (TEM), and a flow cytometry. The concentration and purity of, size, morphology and CD surface markers were confirmed (Figure 1).
엑소좀의 농도를 평가하기 위해서 엑소좀은 하나의 프레임 당 화면으로 확인되는 나노입자수가 30 내지 40 개의 범위 안에 들어올 수 있도록 샘플희석(희석용액; 1X phosphate buffer saline(PBS) solution)을 실시하여 측정하였다(도 1a). 추출한 엑소좀 농도는 평균적으로 1.0 × 1010 particle/mL이고, 평균 크기는 164 nm 내외임을 확인하였다(n=3). In order to evaluate the concentration of exosomes, exosomes are measured by performing sample dilution (dilution solution; 1X phosphate buffer saline (PBS) solution) so that the number of nanoparticles identified on the screen per frame can be within the range of 30 to 40 (FIG. 1A). The extracted exosomes concentration was 1.0 × 10 10 particles / mL on average, it was confirmed that the average size is about 164 nm (n = 3).
추출된 엑소좀의 모양을 투과전자현미경으로 확인하기 위해 1% phosphotungstic acid 용액에 엑소좀 샘플을 1분 동안 처리하여 negative staining을 실시하였다. 그 결과, 구형의 나노입자형태가 관찰되었고, 평균적으로 100 nm 내외의 입자크기를 확인하였다(도 1b).To confirm the shape of the extracted exosomes by transmission electron microscopy, the exosome sample was treated with 1% phosphotungstic acid solution for 1 minute and subjected to negative staining. As a result, spherical nanoparticle morphology was observed, and the average particle size was about 100 nm (FIG. 1B).
또한, 엑소좀 막 표면 마커들로 알려진 CD9, CD63, CD81을 유속분석기를 통해 발현정도를 확인하였다. 마그네틱 비드에 표면마커의 특이적 항체가 결합되어 있는 시약(SBI, CD9/63/81-EXO FLOW Capture kit)과 형광표지인자를 엑소좀 표면에 부착한 후 유속분석기로 엑소좀 표면 마커의 발현을 확인하였다(도 1c). In addition, the expression level of CD9, CD63, and CD81, known as exosome membrane surface markers, were confirmed by flow rate analyzer. After attaching the reagent (SBI, CD9 / 63 / 81-EXO FLOW Capture kit) and the fluorescent marker to which the surface marker specific antibody is bound to the magnetic bead on the surface of the exosome, the expression of the surface marker of the exosome was measured using a flow rate analyzer. It was confirmed (FIG. 1C).
<실시예 3> 엑소좀이 함유된 무혈청 배지에서의 줄기세포 증식유도 평가Example 3 Evaluation of Stem Cell Proliferation Induction in Serum-Free Medium Containing Exosomes
엑소좀이 함유된 무혈청 배양배지는 아래의 표 1과 같이 혼합하여 준비하였다.Serum-free culture medium containing exosomes was prepared by mixing as shown in Table 1 below.
표 1. 엑소좀 무혈청배지 조성 준비 Table 1. Preparation of exosome serum-free medium composition
그룹group GM GM SFMSFM EXO 10EXO 10 EXO 20 EXO 20 EXO 30 EXO 30 EXO 40 EXO 40 EXO 50 EXO 50
배지(DMEM)Badge (DMEM) 10 mL10 mL
우태아혈청(FBS)Fetal Bovine Serum (FBS) 10%10% -- -- -- -- -- ××
Antibiotics1% Antibiotics1% 100 μL100 μL
엑소좀Exosomes -- -- 10 μg/mL10 μg / mL 20 μg/mL20 μg / mL 30 μg/mL30 μg / mL 40 μg/mL40 μg / mL 50 μg/mL50 μg / mL
*GM: Growth medium, positive control*SFM: Serum free medium, negative control * GM: Growth medium, positive control * SFM: Serum free medium, negative control
*EXO 10~50: Serum free medium with exosomes, sample * EXO 10 ~ 50: Serum free medium with exosomes, sample
*Antibiotics: Penicillin/streptomycin* Antibiotics: Penicillin / streptomycin
줄기세포의 증식유도 평가는 인간 지방유래 줄기세포(ASC, 1×104 cell/well)를 48-웰 플레이트(well plate)에서 3일간 배양 후 평가하였다. 세포 증식률은 CCK-8 kit(업체: Dojindo, Cat#: DJB4000X)를 이용하여 흡광도를 측정하였다(n=5). CCK-8 시약은 살아있는 세포 내 탈수소효소와 반응하여 시약의 색소가 변하게 되고 이를 통해 세포 증식률에 대한 정량적인 평가를 실시할 수 있다. 양성대조군으로는 줄기세포 증식배지(GM 그룹; DMEM, 우태아혈청 10%, 페니실린/스트렙토마이신 1%)과 음성대조군으로는 무혈청 배지(SFM 그룹; DMEM, 페니실린/스트렙토마이신 1%)를 사용하였다. Evaluation of proliferation induction of stem cells was evaluated after incubation of human adipose derived stem cells (ASC, 1 × 10 4 cells / well) in a 48-well plate for 3 days. Cell proliferation was measured by using the CCK-8 kit (manufactured by Dojindo, Cat #: DJB4000X) (n = 5). The CCK-8 reagent reacts with live intracellular dehydrogenase to change the pigment of the reagent, which allows quantitative assessment of cell proliferation rate. Stem cell proliferation medium (GM group; DMEM, fetal bovine serum 10%, penicillin / streptomycin 1%) for positive control group and serum-free medium (SFM group; DMEM, penicillin / streptomycin 1%) for negative control group It was.
엑소좀이 함유된 무혈청 배지에서 줄기세포를 배양한 결과, 모든 실험군에서 음성대조군에 비해 증식이 잘 유도되는 것을 유의성 평가를 통해 확인하였고(P < 0.001), 특히 50 ㎍/mL의 엑소좀이 함유된 배지에서는 음성대조군에 비해 2배 이상 세포증식이 잘 유도됨을 확인하였다(도 2). As a result of culturing stem cells in a serum-free medium containing exosomes, it was confirmed through a significant evaluation that proliferation was induced in all experimental groups as compared to the negative control group ( P <0.001), especially 50 ㎍ / mL exosomes It was confirmed that the culture medium is well induced more than two times compared to the negative control group (Fig. 2).
<< 실시예Example 4> 혈청 농도가 다르게 함유된 배양액에서  4> In cultures containing different serum concentrations 엑소좀Exosomes 첨가에 따른 줄기세포 증식향상 평가 Evaluation of Stem Cell Proliferation by Addition
상기 실시예 1에서 분리한 50 ㎍/mL의 엑소좀을 낮은 농도의 혈청, 구체적으로 1%, 3%, 5%의 혈청이 포함된 배양배지에 첨가하여 인간 지방유래 줄기세포의 세포증식 유도향상 평가를 실시하였다(표 2, 도 3). 상기 평가는 인간 지방유래 줄기세포(ASC, 1×104 cell/well)를 48-웰 플레이트(well plate)에서 3일간 배양하면서 평가하였고, 양성대조군은 줄기세포 증식배지(GM 그룹; DMEM, 우태아혈청 10%, 페니실린/스트렙토마이신 1%)를, 음성대조군으로는 무혈청 배지(SFM 그룹; DMEM, 페니실린/스트렙토마이신 1%)를 사용하였다(n=5).Increasing the induction of cell proliferation of human adipose derived stem cells by adding 50 μg / mL of the exosomes isolated in Example 1 to a culture medium containing low serum, specifically 1%, 3%, and 5% serum Evaluation was performed (Table 2, FIG. 3). The evaluation was performed by culturing human adipose derived stem cells (ASC, 1 × 10 4 cells / well) for 3 days in a 48-well plate, and the positive control group was a stem cell proliferation medium (GM group; DMEM, right) Fetal serum 10%, penicillin / streptomycin 1%) and serum-free medium (SFM group; DMEM, penicillin / streptomycin 1%) were used as negative controls (n = 5).
표 2. 혈청 농도별 배지 조성 준비Table 2. Preparation of Medium Composition by Serum Concentration
그룹 group Serum 1%Serum 1% Serum 3%Serum 3% Serum 5%Serum 5% Serum 10%Serum 10%
배지(DMEM)Badge (DMEM) 10 mL10 mL
우태아혈청(FBS)Fetal Bovine Serum (FBS) 1%One% 1%One% 3%3% 3%3% 5%5% 5%5% 10%10%
Antibiotics1%Antibiotics1% 100 μL100 μL
엑소좀(50 μg/mL)Exosome (50 μg / mL) -- ++ -- ++ -- ++ --
*SFM: Serum free medium그 결과, 양성대조군(serum 10%)을 제외한 모든 실험군에서 엑소좀을 처리한 배양조건에서 배양된 줄기세포가 평균적으로 1.5배 이상 세포의 증식률이 향상되는 것을 확인하였다(P < 0.001). * SFM: Serum free medium As a result, it was confirmed that in all experimental groups except the positive control group (serum 10%), the growth rate of the stem cells cultured in the exosome-treated culture conditions improved on average by 1.5 times or more ( P <0.001).
<< 실시예Example 5>  5> 엑소좀이Exosomes 함유된  Contained 무혈청Serum free 배지에서 배양된 줄기세포의  Stem Cells Cultured in Medium 분화능Eruption 평가 evaluation
엑소좀을 함유하는 무혈청 배지에서 배양된 줄기세포의 기능성을 확인하기 위해, 분화 효능 평가를 실시하였다. To confirm the functionality of stem cells cultured in serum-free medium containing exosomes, differentiation efficacy evaluation was performed.
구체적으로, 줄기세포의 분화 효능 평가를 위해 인간 지방유래 줄기세포(ASC, 1×104 cell/well)는 증식배지(DMEM + FBS 10% + P/S 1%)와 엑소좀이 함유된 무혈청배지(DMEM + 50 μg/mL의 엑소좀)에서 3일간 배양하여 세포밀도를 높인 다음, 지방세포(adipocyte) 분화 유도용 배지(DMEM(Dulbecco Modified Eagle Medium high glucose; Gibco, Cat#: 11995065), 5% FBS(fetal bovine serum), 0.5 mM IBMX(Isobutyl-1-methylxanthine; Sigma, Cat# I5879-1G), 10 μg/mL Insulin(Sigma, Cat# I16634-100), 1 μM Dexamethasone(Abcam, Cat# ab12074), 100 μM Indomethacin(Sigma, Cat# I7378-5)으로 교체하여 2주 동안 분화유도 실시하였다. 지방세포로의 분화 평가를 위해서 Oil red O 염색법을 이용하여 평가하였다. 그 결과, 엑소좀이 함유된 무혈청 배지에서 배양된 인간 지방유래 줄기세포는 지방세포에서 특이적으로 관찰되는 oil-droplet이 형성된 것으로 확인하였다(도 4). Specifically, in order to evaluate the differentiation efficacy of stem cells, human adipose derived stem cells (ASC, 1 × 10 4 cell / well) are radish containing proliferation medium (DMEM + FBS 10% + P / S 1%) and exosomes. Incubate in serum medium (DMEM + 50 μg / mL exosomes) for 3 days to increase cell density, and then to induce adipocyte differentiation medium (DMEM (Dulbecco Modified Eagle Medium high glucose; Gibco, Cat #: 11995065) , 5% FBS (fetal bovine serum), 0.5 mM IBMX (Isobutyl-1-methylxanthine; Sigma, Cat # I5879-1G), 10 μg / mL Insulin (Sigma, Cat # I16634-100), 1 μM Dexamethasone (Abcam, Cat # ab12074) and 100 μM Indomethacin (Sigma, Cat # I7378-5) were used for differentiation induction for 2 weeks, and oil red O staining was used to evaluate differentiation into adipocytes. Human adipose derived stem cells cultured in the serum-free medium containing it was confirmed that the oil-droplet was formed specifically observed in fat cells (Fig. 4). ).
따라서, 인간 지방유래 줄기세포로부터 생산된 엑소좀은 인간 지방유래 줄기세포의 분화능을 유지하면서 세포 증식에 도움을 주는 유효한 성분임을 확인할 수 있었다. Therefore, the exosomes produced from human adipose derived stem cells were found to be effective ingredients that help cell proliferation while maintaining the differentiation ability of human adipose derived stem cells.
이상 본 발명을 상기 실시예를 들어 설명하였으나, 본 발명은 이에 제한되는 것이 아니다. 당업자라면 본 발명의 취지 및 범위를 벗어나지 않고 수정, 변경을 할 수 있으며 이러한 수정과 변경 또한 본 발명에 속하는 것임을 알 수 있을 것이다.Although the present invention has been described with reference to the above embodiments, the present invention is not limited thereto. Those skilled in the art can make modifications and changes without departing from the spirit and scope of the present invention, and it will be appreciated that such modifications and changes also belong to the present invention.

Claims (17)

  1. 인간줄기세포 유래 엑소좀을 유효성분으로 함유하는 세포 배양용 무혈청 배지 조성물.A serum-free medium composition for cell culture containing human stem cell-derived exosomes as an active ingredient.
  2. 제1항에 있어서,The method of claim 1,
    상기 인간줄기세포는 인간 골수유래 줄기세포 및 인간 지방유래 줄기세포로 구성된 군으로부터 선택된 1 이상인 것을 특징으로 하는 세포 배양용 무혈청 배지 조성물.The human stem cell is serum-free medium composition for cell culture, characterized in that at least one selected from the group consisting of human bone marrow-derived stem cells and human adipose derived stem cells.
  3. 제2항에 있어서,The method of claim 2,
    상기 인간 지방유래 줄기세포에서 유래된 엑소좀을 유효성분으로 함유하고, 동물 혈청을 포함하지 않은 것을 특징으로 하는 세포 배양용 무혈청 배지 조성물. Serum-free medium composition for cell culture, characterized in that it contains exosomes derived from human adipose derived stem cells as an active ingredient and does not contain animal serum.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서,The method according to any one of claims 1 to 3,
    줄기세포의 배양에 사용되는 것을 특징으로 하는 세포 배양용 무혈청 배지 조성물.Serum-free medium composition for cell culture, characterized in that used for the culture of stem cells.
  5. 제1항 내지 제3항 중 어느 한 항에 있어서,The method according to any one of claims 1 to 3,
    상기 엑소좀은 기본 배지에 0.01 내지 1,000 μg/mL의 농도로 함유된 세포 배양용 무혈청 배지 조성물.The exosomes are serum-free medium composition for cell culture contained in a concentration of 0.01 to 1,000 μg / mL in the basal medium.
  6. 제5항에 있어서,The method of claim 5,
    상기 기본 배지는 DMEM(Dulbecco’s Modified Eagle’s Medium), MEM(Minimal Essential Medium), RPMI 1640, F-10, F-12, a-MEM(a-Mineral Essential Medium), G-MEM(Glasgow’s Mineral Essential Medium), 및 IMDM(Iscove’s Modified Dulbecco’s Medium)으로 구성된 군으로부터 선택된 1 이상인 것을 특징으로 하는 세포 배양용 무혈청 배지 조성물. The basal medium includes Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), RPMI 1640, F-10, F-12, a-Mineral Essential Medium (G-MEM), and Glasgow's Mineral Essential Medium (G-MEM). And, serum-free medium composition for cell culture, characterized in that at least one selected from the group consisting of IMDM (Iscove's Modified Dulbecco's Medium).
  7. 인간줄기세포 유래 엑소좀을 포함하는 동물혈청 대체제.Animal serum substitutes, including human stem cell-derived exosomes.
  8. 제7항에 있어서,The method of claim 7, wherein
    상기 인간줄기세포는 인간 골수유래 줄기세포 및 인간 지방유래 줄기세포로 구성된 군으로부터 선택된 1 이상인 것을 특징으로 하는 동물혈청 대체제.The human stem cells are animal bone substitutes, characterized in that at least one selected from the group consisting of human bone marrow-derived stem cells and human adipose derived stem cells.
  9. 제7항 또는 제8항에 있어서,The method according to claim 7 or 8,
    줄기세포의 배양에 사용되는 것을 특징을 하는 동물혈청 대체제.Animal serum substitute, characterized in that used in the culture of stem cells.
  10. 인간줄기세포로부터 엑소좀을 분리하는 단계;Separating exosomes from human stem cells;
    분리된 엑소좀을 포함하는 세포 배양용 무혈청 배지 조성물을 준비하는 단계; 및 Preparing a serum-free medium composition for cell culture comprising the isolated exosomes; And
    세포를 상기 세포 배양용 무혈청 배지 조성물에 배양하는 단계를 포함하는 세포 배양 방법.Cell culture method comprising the step of culturing the cells in the serum-free medium composition for cell culture.
  11. 제10항에 있어서,The method of claim 10,
    상기 인간줄기세포는 인간 골수유래 줄기세포 및 인간 지방유래 줄기세포로 구성된 군으로부터 선택된 1 이상인 것을 특징으로 하는 세포 배양 방법.The human stem cell is a cell culture method, characterized in that at least one selected from the group consisting of human bone marrow-derived stem cells and human adipose derived stem cells.
  12. 제10항에 있어서,The method of claim 10,
    상기 세포 배양용 무혈청 배지 조성물은 인간 지방유래 줄기세포에서 유래된 엑소좀을 유효성분으로 함유하고, 동물 혈청을 포함하지 않는 것을 특징으로 하는 세포 배양 방법.The cell culture-free serum medium composition contains an exosome derived from human adipose derived stem cells as an active ingredient and does not contain animal serum.
  13. 제10항 내지 제12항 중 어느 한 항에 있어서,The method according to any one of claims 10 to 12,
    줄기세포의 배양에 사용되는 것을 특징으로 하는 세포 배양 방법.Cell culture method, characterized in that used for the culture of stem cells.
  14. 제10항 내지 제12항 중 어느 한 항에 있어서,The method according to any one of claims 10 to 12,
    상기 세포 배양용 무혈청 배지 조성물은 상기 분리된 엑소좀이 기본 배지에 0.01 내지 1,000 μg/mL의 농도로 함유된 세포 배양 방법.The cell culture-free serum medium composition is a cell culture method containing the separated exosomes in a concentration of 0.01 to 1,000 μg / mL in the basal medium.
  15. 제14항에 있어서,The method of claim 14,
    상기 기본 배지는 DMEM(Dulbecco’s Modified eagle’s Medium), MEM(Minimal Essential Medium), RPMI 1640, F-10, F-12, a-MEM(a-Mineral Essential Medium), G-MEM(Glasgow’s Mineral Essential Medium), 및 IMDM(Iscove’s Modified Dulbecco’s Medium)으로 구성된 군으로부터 선택된 1 이상인 것을 특징으로 하는 세포 배양 방법.The basal medium is Dulbecco's Modified eagle's Medium (DMEM), Minimal Essential Medium (MEM), RPMI 1640, F-10, F-12, a-Mineral Essential Medium (G-MEM), and Glasgow's Mineral Essential Medium (G-MEM). And, and cell culture method characterized in that at least one selected from the group consisting of IMDM (Iscove's Modified Dulbecco's Medium).
  16. 제1항에 있어서,The method of claim 1,
    상기 조성물은 인간 지방유래 줄기세포에서 유래된 엑소좀을 유효성분으로 함유하고, 동물 혈청을 실질적으로 포함하지 않는 것을 특징으로 하는 세포 배양용 무혈청 배지 조성물.The composition contains a exosome derived from human adipose derived stem cells as an active ingredient, serum-free medium composition for cell culture, characterized in that substantially no animal serum.
  17. 제16항에 있어서, The method of claim 16,
    상기 동물 혈청을 실질적으로 포함하지 않는 조성물은 전체 조성물 중에 동물 혈청을 0 내지 5 중량%의 농도로 포함하는 것을 특징으로 하는 세포 배양용 무혈청 배지 조성물.The serum-free medium composition for cell culture, characterized in that the composition substantially free of animal serum comprises animal serum in a concentration of 0 to 5% by weight in the total composition.
PCT/KR2018/006488 2017-06-07 2018-06-07 Serum-free medium composition for culturing cells including exosome derived from human stem cell WO2018226051A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0070592 2017-06-07
KR20170070592 2017-06-07

Publications (2)

Publication Number Publication Date
WO2018226051A2 true WO2018226051A2 (en) 2018-12-13
WO2018226051A3 WO2018226051A3 (en) 2019-03-21

Family

ID=64567074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/006488 WO2018226051A2 (en) 2017-06-07 2018-06-07 Serum-free medium composition for culturing cells including exosome derived from human stem cell

Country Status (2)

Country Link
KR (1) KR102144593B1 (en)
WO (1) WO2018226051A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110938593A (en) * 2020-01-02 2020-03-31 张伟 Crocodile adipose-derived stem cell exosome extraction and freeze-dried powder preparation method
CN113234663A (en) * 2021-05-10 2021-08-10 博品(上海)生物医药科技有限公司 Method for culturing endometrial cells
CN114207116A (en) * 2019-07-30 2022-03-18 韩国外泌体生技有限公司 Novel exosome production method and application thereof
CN114836375A (en) * 2020-12-31 2022-08-02 国典(北京)医药科技有限公司 Exosome secretion inducer, induction culture medium and application thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021091185A1 (en) * 2019-11-05 2021-05-14 주식회사 한국줄기세포뱅크 Composition for cell culture, comprising paracrine factor
KR102558281B1 (en) * 2020-03-04 2023-07-25 주식회사 엠디헬스케어 Composition for regulating stem cell function comprising Lactobacillus Bacteria-derived extracellular vesicles as an active ingredient
WO2021201637A1 (en) * 2020-04-01 2021-10-07 주식회사 프리모리스 Method for preparing culture medium containing high levels of high-potency exosomes secreted by cord blood stem cells, and use thereof
KR102253418B1 (en) * 2020-10-08 2021-05-18 (주)지에프씨생명과학 Composition comprising an exosome derived from skin lactic acid bacteria as an active ingredient
WO2022191341A1 (en) * 2021-03-08 2022-09-15 주식회사 엑소스템텍 Pharmaceutical composition comprising stem cell-derived exosome for palliating or treating arthritis
KR20230150223A (en) * 2022-04-20 2023-10-30 주식회사 아모그린텍 Extracellular vesicles production system and method for production of extracellular vesicles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080042761A (en) 2006-11-10 2008-05-15 문찬일 Method for proliferating stem cells with leptin
KR101220239B1 (en) 2008-04-01 2013-01-09 바이오스펙트럼 주식회사 Composition for Promoting Stem Cell Proliferation Comprising Vegetable Peptone
KR20110097064A (en) * 2010-02-24 2011-08-31 (주) 아크스템 Serum free media for stem cell culture, tissue regeneration composition including the same, and method of tissue regeneration using the same
KR101026070B1 (en) 2010-06-22 2011-03-31 주식회사 엘컴사이언스 Process for culturing epidermal skin stem cells and composition for wrinkle-caring or promoting hair growth comprising the epidermal skin stem cells obtained by the process
KR101639988B1 (en) * 2011-05-11 2016-07-15 (주)안트로젠 Method for preparation of mesenchymal stem cell culture comprising high concentration of cell growth factors and composition prepared therefrom
WO2013009100A2 (en) * 2011-07-11 2013-01-17 (주)차바이오메드 Method for manufacturing umbilical cord extract and usage of same
US9982233B2 (en) * 2013-12-12 2018-05-29 Samsung Life Public Welfare Foundation Method for promoting generation of stem cell-derived exosome by using thrombin
KR102153635B1 (en) 2014-01-21 2020-09-08 주식회사 엘지생활건강 Serum-free medium composition for stem cell culture and methods for culturing stem cell
KR102153637B1 (en) 2014-01-21 2020-09-08 주식회사 엘지생활건강 Serum-free medium composition for stem cell culture and methods for culturing stem cell
KR102153636B1 (en) 2014-01-21 2020-09-08 주식회사 엘지생활건강 Serum-free medium composition for stem cell culture and methods for culturing stem cell
JP2017506511A (en) * 2014-02-14 2017-03-09 ナショナル ユニバーシティー オブ アイルランド, ゴールウェイ Serum-free medium
KR101629151B1 (en) * 2014-11-07 2016-06-10 한양대학교 에리카산학협력단 Composition including stem cell-derived exosome for inducing adipogenic differentiation and adipose tissue regeneration
KR101706642B1 (en) * 2015-02-04 2017-02-17 주식회사 엑소스템텍 Composition comprising exosomes extracted from stem cells which differentiate into chondrocytes for inducing chondrogenic differentiation or regenerating cartilage tissue
WO2017001649A1 (en) * 2015-07-02 2017-01-05 Med Cell Europe Ag Secretomes and method for producing secretomes
KR101707622B1 (en) 2016-11-18 2017-02-20 주식회사 디지레이 serum-free medium composition for proliferation of mesenchymal stem cell

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114207116A (en) * 2019-07-30 2022-03-18 韩国外泌体生技有限公司 Novel exosome production method and application thereof
CN114207116B (en) * 2019-07-30 2024-03-15 韩国外泌体生技有限公司 New exosome production method and application thereof
CN110938593A (en) * 2020-01-02 2020-03-31 张伟 Crocodile adipose-derived stem cell exosome extraction and freeze-dried powder preparation method
CN114836375A (en) * 2020-12-31 2022-08-02 国典(北京)医药科技有限公司 Exosome secretion inducer, induction culture medium and application thereof
CN114836375B (en) * 2020-12-31 2023-07-21 国典(北京)医药科技有限公司 Exosome secretion inducer, induction medium and application thereof
CN113234663A (en) * 2021-05-10 2021-08-10 博品(上海)生物医药科技有限公司 Method for culturing endometrial cells

Also Published As

Publication number Publication date
WO2018226051A3 (en) 2019-03-21
KR102144593B1 (en) 2020-08-13
KR20180133812A (en) 2018-12-17

Similar Documents

Publication Publication Date Title
WO2018226051A2 (en) Serum-free medium composition for culturing cells including exosome derived from human stem cell
EP3081223B1 (en) Method for promoting generation of stem cell-derived exosome by using thrombin
WO2018182356A1 (en) Culture containing high concentration of mesenchymal stem cell-derived high-purity exosome, and preparation method therefor
US11339372B2 (en) Serum-free medium inducing differentiation of umbilical cord mesenchymal stem cell into insulin-secretion-like cell and preparation method and use thereof
US20230117670A1 (en) Bioactive substance composition, serum-free medium comprising the composition, and uses thereof
WO2021054576A1 (en) Method for promoting generation of exosomes and/or extracellular vesicles
WO2021020726A1 (en) Novel exosome production method and application thereof
KR102136172B1 (en) Method for production of human stem cell conditioned medium comprising cell growth-regulating proteins
KR101877793B1 (en) Serum-Free Medium Composition for Stem Cell Culture and Methods for Culturing Stem Cells Using the Same
WO2021254296A1 (en) Bioactive substance composition, serum-free culture medium comprising the composition, and uses thereof
KR102292132B1 (en) Serum-free medium composition
WO2016068596A1 (en) Medium composition for culturing stem cells
WO2013085303A1 (en) Canine amniotic membrane-derived multipotent stem cells
TWI285219B (en) Method and composition for inducing neural differentiation
KR20160108190A (en) Pharmaceutical composition for the prevention or treatment of a lung disease comprising mesenchymal stem cells having improved proliferation and differentiation capacity
WO2024049158A1 (en) Isolation and culture conditions of peripheral blood-derived stem cells, and induction of differentiation into progenitor cells by using same
CN115125192B (en) Bone marrow supernatant and application thereof in cell culture
WO2013077639A1 (en) Equine amniotic membrane-derived mesenchymal stem cells
WO2017052270A1 (en) Composition for promoting cell proliferation, and culture medium including same for culturing cells
KR20150091519A (en) A method of generating multilineage potential cells
WO2019221477A1 (en) Composition for promoting stem cell differentiation, comprising progenitor cell culture solution and multilayer graphene film, and use thereof
CN115427549A (en) Culture medium for stem cells and method for culturing stem cells
CN112680410A (en) Method for inducing pluripotent stem cells to culture heart fibroblasts in differentiation mode and culture solution thereof
WO2019004800A2 (en) Stem cell-derived skin precursor cell culture medium and preparation method therefor
KR101538969B1 (en) Medium Composition for Culturing Mesenchymal Stem Cells Comprising Extract of Ecklonia cava

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18812706

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18812706

Country of ref document: EP

Kind code of ref document: A2